Literature DB >> 15164161

The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure.

Takao Tsuchida1, Eiji Ishimura, Takami Miki, Naoki Matsumoto, Hiroshi Naka, Shuichi Jono, Masaaki Inaba, Yoshiki Nishizawa.   

Abstract

Several new serum markers for bone metabolism have recently become available and are being applied to clinical practice. Their clinical usefulness in predialysis patients with chronic renal failure (CRF), however, has not yet been determined. Serum levels of three bone formation markers-bone alkaline phosphatase (BAP), osteocalcin (OC), and N-terminal propeptide of type I collagen (PINP)-and three bone resorption markers-type I collagen cross-linked N-telopeptide (NTx), deoxypyridinoline (DPD), and pyridinoline (PYD)-were measured simultaneously in 85 predialysis CRF patients (serum creatinine 3.5 +/- 1.9 mg/dl, 61.0 +/- 10.9 years old, 54 males and 31 females, 36 diabetics and 49 nondiabetics) to examine the relationships between these markers and bone mineral density (BMD) of the distal radius, as measured by peripheral quantitative computed tomography (pQCT). Trabecular BMD, which is strongly affected by bone metabolism, was significantly negatively correlated with each of the bone formation markers (r=-0.341, p=0.0016, for OC; r=-0.314, p=0.0036, for PINP; r=-0.238, p=0.0315, for BAP), but there was no significant correlation between BMD and any of the bone resorption markers. In multivariate regression analyses (adjusted by age, sex, presence of diabetes, glomerular filtration rate, intact parathyroid hormone, calcium, phosphate, and 1,25-dihydroxyvitamin D), OC and PINP were significantly associated with a decrease in BMD, but BAP was not. In conclusion, we demonstrated that in predialysis CRF patients, BMD of the distal radius, particularly of trabecular bone, is associated with serum OC and PINP levels. OC and PINP are suggested to be possible parameters for the clinical evaluation of the effect of bone metabolism on BMD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164161     DOI: 10.1007/s00198-004-1655-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  45 in total

1.  A new serum assay to measure N-terminal fragment of telopeptide of type I collagen in patients with renal osteodystrophy.

Authors:  A Montagnani; S Gonnelli; C Cepollaro; M Mangeri; S Martini; M B. Franci; M S. Campagna; B Lucani; N Di Paolo; G Bellucci; C Gennari
Journal:  Eur J Intern Med       Date:  2003-05       Impact factor: 4.487

2.  Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis.

Authors:  Y Furumitsu; M Inaba; K Yukioka; M Yukioka; Y Kumeda; Y Azuma; T Ohta; T Ochi; Y Nishizawa; H Morii
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

3.  Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure.

Authors:  J Przedlacki; J Manelius; K Huttunen
Journal:  Nephron       Date:  1995       Impact factor: 2.847

Review 4.  Renal osteodystrophy in chronic renal failure.

Authors:  L Tammy Ho; Stuart M Sprague
Journal:  Semin Nephrol       Date:  2002-11       Impact factor: 5.299

5.  Rapid bone loss is associated with increased levels of biochemical markers.

Authors:  P D Ross; W Knowlton
Journal:  J Bone Miner Res       Date:  1998-02       Impact factor: 6.741

6.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

7.  Cut-off values determined for vertebral fracture by peripheral quantitative computed tomography in Japanese women.

Authors:  I Gorai; K Nonaka; H Kishimoto; H Sakata; Y Fujii; T Fujita
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

8.  Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients.

Authors:  An R J Bervoets; Goce B Spasovski; Geert J Behets; Geert Dams; Momir H Polenakovic; Katica Zafirovska; Viviane O Van Hoof; Marc E De Broe; Patrick C D'Haese
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

9.  Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.

Authors:  Misako Ueda; Masaaki Inaba; Senji Okuno; Kyoko Nagasue; Kayoko Kitatani; Eiji Ishimura; Motokazu Shimizu; Takami Miki; Masao Kim; Yoshiki Nishizawa
Journal:  Am J Kidney Dis       Date:  2002-10       Impact factor: 8.860

10.  Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease.

Authors:  A J Hutchison; R W Whitehouse; H F Boulton; J E Adams; E B Mawer; T J Freemont; R Gokal
Journal:  Kidney Int       Date:  1993-11       Impact factor: 10.612

View more
  10 in total

1.  Annual change in bone mineral density in predialysis patients with chronic renal failure: significance of a decrease in serum 1,25-dihydroxy-vitamin D.

Authors:  Naoko Obatake; Eiji Ishimura; Takao Tsuchida; Kaname Hirowatari; Hiroshi Naka; Yasuo Imanishi; Takami Miki; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

Review 2.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

3.  Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.

Authors:  S Geng; Z Kuang; P L Peissig; D Page; L Maursetter; K E Hansen
Journal:  Osteoporos Int       Date:  2019-05-31       Impact factor: 4.507

4.  High FGF23 levels are associated with impaired trabecular bone microarchitecture in patients with osteoporosis.

Authors:  T Rupp; S Butscheidt; E Vettorazzi; R Oheim; F Barvencik; M Amling; T Rolvien
Journal:  Osteoporos Int       Date:  2019-05-01       Impact factor: 4.507

5.  Discriminants of prevalent fractures in chronic kidney disease.

Authors:  Thomas L Nickolas; Serge Cremers; Amy Zhang; Valeri Thomas; Emily Stein; Adi Cohen; Ryan Chauncey; Lucas Nikkel; Michael T Yin; Xiaowei S Liu; Stephanie Boutroy; Ronald B Staron; Mary B Leonard; Donald J McMahon; Elzbieta Dworakowski; Elizabeth Shane
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

Review 6.  Chronic kidney disease and bone fracture: a growing concern.

Authors:  Thomas L Nickolas; Mary B Leonard; Elizabeth Shane
Journal:  Kidney Int       Date:  2008-06-18       Impact factor: 10.612

7.  Rapid cortical bone loss in patients with chronic kidney disease.

Authors:  Thomas L Nickolas; Emily M Stein; Elzbieta Dworakowski; Kyle K Nishiyama; Mafo Komandah-Kosseh; Chiyuan A Zhang; Donald J McMahon; Xiaowei S Liu; Stephanie Boutroy; Serge Cremers; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

8.  Matrix metalloproteinase-1 and -2 as markers of mineral bone disease in chronic kidney disease patients.

Authors:  K Thisiadou; V Liakopoulos; G Dimas; G Koliakos; M Karamouzis
Journal:  Hippokratia       Date:  2017 Jan-Mar       Impact factor: 0.471

9.  Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study.

Authors:  Hanne Skou Jørgensen; Simon Winther; Morten Bøttcher; Ellen-Margrethe Hauge; Lars Rejnmark; My Svensson; Per Ivarsen
Journal:  BMC Nephrol       Date:  2017-09-06       Impact factor: 2.388

10.  Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study.

Authors:  Te-Hui Kuo; Wei-Hung Lin; Jo-Yen Chao; An-Bang Wu; Chin-Chung Tseng; Yu-Tzu Chang; Hung-Hsiang Liou; Ming-Cheng Wang
Journal:  BMC Nephrol       Date:  2019-07-17       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.